Intraoperative Immunohistochemistry Enhances Detection of Low-Volume Sentinel Lymph Node Metastases in Breast Cancer

Breast cancer treatment has undergone a quiet revolution in recent decades, shifting away from the routine removal of all underarm lymph nodes toward a more precise approach. Instead of clearing the entire area, surgeons now often perform a sentinel lymph node biopsy, removing just the first few nodes that drain fluid from the tumor. These nodes act as the body's primary sentinels; if they are free of cancer, the disease has likely not spread further, sparing the patient from the swelling and pain that can follow a more extensive surgery. However, this precision relies entirely on the ability of a pathologist to examine these tiny nodes while the patient is still on the operating table. If the surgeon finds cancer in the node during the operation, they may need to remove more nodes immediately. If they miss a small amount of cancer, the patient might return for a second surgery later, or worse, receive insufficient treatment. The challenge lies in spotting the smallest traces of cancer cells, which can be so few or so subtle that they hide easily within the complex tissue of a lymph node.

For years, the standard method for this quick, on-the-spot check has been to freeze the tissue, slice it thinly, and stain it with a blue and pink dye to look for abnormalities under a microscope. While this works well for large clusters of cancer cells, it often fails to catch the smallest deposits, known as isolated tumor cells or micrometastases. These tiny groups of cells can look very similar to normal, healthy cells that happen to be swollen or reactive, leading to a false sense of security. In a new study, researchers at the Second Xiangya Hospital of Central South University tested whether adding a specific chemical stain to this quick process could help pathologists see these hidden cells more clearly. They focused on a technique called immunohistochemistry, which uses antibodies to hunt down a specific protein found in breast cancer cells but not in normal lymph node cells. By applying this stain to the frozen tissue in real time, they aimed to see if it could catch the cancer that the standard dye missed.

The team looked back at records from 295 patients who had undergone surgery for breast cancer. They divided the group into two sets: 100 patients who were known to have large, obvious cancer deposits in their nodes, and 195 patients who had the smaller, harder-to-find types of spread. For the smaller cases, the researchers compared how well junior pathologists and senior pathologists could identify the cancer using only the standard blue and pink stain versus using that stain combined with the rapid chemical hunt. They also compared these quick, on-the-spot guesses against the final, definitive diagnosis made after the tissue was processed in the lab over several days. The results showed a clear gap in performance based on experience. When relying only on the standard stain, junior pathologists missed the diagnosis in more than half of the cases where small cancer deposits were present. Even the senior pathologists, with decades of experience, missed about fifteen percent of these small deposits.

The addition of the rapid chemical stain changed the picture significantly. When the senior pathologists used the extra stain, their ability to correctly identify the small cancer deposits jumped to over ninety percent. The stain acted like a highlighter, making the cancer cells glow against the background tissue, which made them impossible to confuse with normal cells. This was particularly important because the chemical stain helped distinguish cancer from common mimics, such as swollen blood vessel cells or clusters of immune cells that often look like cancer under a microscope but are actually harmless. The study found that the chemical stain reduced the number of mistakes made by the senior pathologists by more than half, bringing their accuracy close to that of a perfect diagnosis. For the junior pathologists, the stain also helped, though the study focused most heavily on the improvement seen in the experienced team.

The researchers also looked at what factors made the cancer harder to find. They discovered that the size of the cancer deposit and the number of nodes involved were key factors in whether a junior pathologist would make a mistake. Smaller deposits and fewer affected nodes were more likely to be overlooked. Interestingly, the study also found a link between the type of breast cancer and how it spread. Patients with a specific type of cancer that does not respond to a hormone called HER2 were more likely to have the smallest, hardest-to-detect deposits, while those with larger deposits were more common in other subtypes. This suggests that the biology of the tumor itself influences how it hides in the lymph nodes.

The implications of these findings are practical and immediate. By integrating this rapid chemical stain into the standard operating room workflow, surgeons can get a much more reliable answer while the patient is still under anesthesia. This reduces the likelihood of a patient needing a second surgery to remove more lymph nodes because the first check missed a small amount of cancer. The process takes only about twenty minutes to complete, fitting easily into the time already spent on the operation, and uses standard equipment available in most hospitals. While the study was retrospective, meaning it looked at past data rather than testing the method on new patients in real time, the results strongly suggest that this dual-method approach offers a robust way to improve diagnostic accuracy. It bridges the gap between the speed needed in the operating room and the precision required to make life-altering decisions about cancer treatment, ensuring that the most vulnerable patients receive the right care the first time.